Fig. 1. CBF and Tmax maps derived from the model and CTP showing three patients with different cores and low perfusion volumes in the test dataset and the corresponding maximum intensity projection ...
SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated, more ...
Topline Data from Three Phase 3 Studies Evaluating DT120 Orally Disintegrating Tablet (ODT) for GAD and MDD Expected in 2026: Voyage in 2Q, Panorama in 2H, and Emerge Mid-Year Company Presenting at ...
Phase 1/2 OMAHA-01A substudy of oral CYP11A1 inhibitor opevesostat alone or in combination with other therapies for metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results